$CDLX

All You Need to Know About Cardlytics (CDLX) Rating Upgrade to Buy

Cardlytics (CDLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 10, 2025, 5:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 11, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
All You Need to Know About Cardlytics (CDLX) Rating Upgrade to Buy — source image
Decision brief

The 30-second read

$CDLXBullishMed
01

Why it matters

The upgrade may lead to increased buying interest, potentially driving the stock higher in the short term.

02

Market read

The news is relevant for investors interested in the digital marketing and analytics sector, with a focus on Cardlytics.

03

What to watch

Broader market downturns or sector-specific headwinds could negate the positive sentiment.

Timing: Immediate, as the upgrade was recent.

Background

Cardlytics received an upgrade to a Zacks Rank #2 (Buy), reflecting increased optimism about its earnings prospects.

Company-level read

Ticker impact

$CDLXBullishMedium confidence
Context

High relevance due to recent upgrade and positive sentiment.

Expected impact

Moderate increase in short to medium term, approximately 5-10%.

Evidence & confidence

The upgrade indicates improved analyst confidence, which may attract buyers. However, limited technical momentum and overall market conditions suggest cautious optimism.

Market effects

Potential positive impact on the Technology and Financial Markets sectors, especially related to digital advertising and marketing analytics.

Primarily US-based, with possible ripple effects in global markets due to sector relevance.

Limited; impact is mostly regional and sector-specific.

Counterpoint

The positive upgrade may already be priced in; potential overestimation of earnings prospects could lead to a correction.

Key entities

  • Cardlytics

    A marketing analytics and loyalty platform provider.

  • Zacks

    Provider of investment research and stock ratings.

Related articles

$CDLXMedAI 8/10

Cardlytics: Q2 Earnings Snapshot

Cardlytics (CDLX) reported a Q2 loss of $14.9 million, or $2.58 per share. Adjusted for discontinued operations, the loss was $1.50 per share. Revenue was $36.9 million. For the quarter ending September, the company expects revenue of $34 million to $39 million.

$CDLXMed

Cardlytics, Inc. (CDLX): Results of Operations and Financial Condition

Cardlytics, Inc. (CDLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cdlx_form8-kx2026q2xex991.htm EX-99.1 Document Exhibit 99.1 Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance • Company delivers strong second quarter results: ◦ Revenues of $36.9 million ◦ Billings of $65.5 million ◦ Adjusted Con

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.